Harbin Pharmaceutical Group Co., Ltd. (600664.SS)
CNY 3.97
(0.0%)
CNY 3.97
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 950.26 Million | 622.09 Million | -162.43 Million | -728.15 Million | -284.93 Million | 692.72 Million |
| Net Income | 395.26 Million | 511.08 Million | 409.84 Million | -1.04 Billion | 121.86 Million | 403.63 Million |
| Depreciation & Amortization | 304.39 Million | 310.39 Million | 307.54 Million | 369.75 Million | 397.86 Million | 422.47 Million |
| Deferred income taxes | 2.96 Million | -575.16 Thousand | 3.49 Million | -189.4 Million | 12.25 Million | 11.54 Million |
| Stock-based compensation | 3.24 Million | 3.68 Million | 8.75 Million | - | - | 5.66 Million |
| Change in working capital | 31.2 Million | -163.64 Million | -807.01 Million | -403.74 Million | -762.52 Million | -180.99 Million |
| Other non-cash items | 794.01 Million | -38.86 Million | -85.05 Million | 351.08 Million | -42.14 Million | 47.61 Million |
| Investing Cash Flow | -207.23 Million | 72.33 Million | 91.61 Million | -101.16 Million | -1.37 Billion | -804.11 Million |
| Investments in PPE | -86.53 Million | -89.64 Million | -76.69 Million | -118.21 Million | -38.99 Million | -114.11 Million |
| Acquisitions | 35.93 Million | 151.03 Million | 177.46 Million | 15.18 Million | 2.92 Million | 115.66 Million |
| Investment purchases | -589.47 Thousand | -151.03 Million | -177.46 Million | -15.18 Million | -1.36 Billion | -692.35 Million |
| Sales/Maturities of investments | 589.47 Thousand | 860.71 Thousand | 848.82 Thousand | 1.83 Million | 699.5 Thousand | 796.69 Thousand |
| Other Investing Activities | -156.63 Million | 161.12 Million | 167.46 Million | 15.2 Million | 20.74 Million | -114.11 Million |
| Financing Cash Flow | 147.94 Million | 174.61 Million | 393.26 Million | 1.06 Billion | 287.53 Million | -1.36 Billion |
| Debt repayment | -177.47 Million | -2.03 Billion | -1.17 Billion | -525.44 Million | -116.97 Million | -125.75 Million |
| Dividends payments | -44.15 Million | -54.3 Million | -61.54 Million | -24.09 Million | -10.33 Million | -1.35 Billion |
| Common Stock Repurchased | -8.36 Million | -16.97 Million | -15.53 Million | - | -114.31 Million | - |
| Common Stock Issuance | 3.72 Million | 16.97 Million | 15.53 Million | - | 114.31 Million | - |
| Other Financing Activities | 372.45 Million | 2.25 Billion | 1.62 Billion | 1.6 Billion | 414.84 Million | 114.97 Million |
| Accounts receivables | -94.41 Million | -237.95 Million | -613.93 Million | -569.32 Million | -1 Billion | 375.19 Million |
| Accounts payables | 245.2 Million | -202.97 Million | -30.1 Million | 230.33 Million | 511.56 Million | -593.17 Million |
| Inventory | -119.58 Million | 277.85 Million | -166.45 Million | 124.64 Million | -277.59 Million | 25.44 Million |
| Other working capital | -2.00 | -575.16 Thousand | 3.49 Million | -189.4 Million | 12.25 Million | -206.43 Million |
| Cash at beginning of period | 2.43 Billion | 1.19 Billion | 871.91 Million | 640.69 Million | 2.01 Billion | 3.48 Billion |
| Cash at end of period | 3.06 Billion | 2.06 Billion | 1.19 Billion | 871.91 Million | 640.69 Million | 2.01 Billion |
| Capital Expenditure | -86.53 Million | -89.64 Million | -76.69 Million | -118.21 Million | -38.99 Million | -114.11 Million |
| Effect of forex changes on cash | 923.88 Thousand | 3.74 Million | -2.9 Million | -872.5 Thousand | -1.29 Million | - |
| Net cash flow / Change in cash | 626.9 Million | 872.78 Million | 319.53 Million | 231.22 Million | -1.37 Billion | -1.47 Billion |
| Free Cash Flow | 863.72 Million | 532.44 Million | -239.13 Million | -846.36 Million | -323.93 Million | 578.61 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 164.9 Million | 166.64 Million | 176.74 Million | 395.26 Million | 104.76 Million | 107.78 Million |
| Depreciation & Amortization | - | 74.59 Million | 74.59 Million | 304.39 Million | 76.1 Million | -144.46 Million |
| Deferred income taxes | - | - | - | 2.96 Million | -42.96 Million | -152.8 Million |
| Stock-based compensation | - | - | - | 3.24 Million | 954.69 Thousand | 954.69 Thousand |
| Change in working capital | - | -107.28 Million | - | 31.2 Million | 42 Million | 298.01 Million |
| Other non-cash items | -59.86 Million | 252.37 Million | -447.54 Million | 794.01 Million | -36.71 Million | 166.85 Million |
| Investing Cash Flow | -35.33 Million | -15.62 Million | -14.74 Million | -207.23 Million | -45.71 Million | -137.4 Million |
| Investments in PPE | -36.15 Million | -15.9 Million | -14.74 Million | -86.53 Million | -46.19 Million | -14.8 Million |
| Acquisitions | 822.73 Thousand | 288.62 Thousand | 3770.14 | 35.93 Million | 483.51 Thousand | 33.45 Million |
| Investment purchases | - | -10 Thousand | - | -589.47 Thousand | 1.00 | -33.94 Million |
| Sales/Maturities of investments | - | - | - | 589.47 Thousand | -498 Thousand | 498 Thousand |
| Other Investing Activities | 822.73 Thousand | 278.62 Thousand | 3770.00 | -156.63 Million | 498 Thousand | -122.59 Million |
| Financing Cash Flow | -173.44 Million | 15.19 Million | 126.26 Million | 147.94 Million | 179.61 Million | 3.29 Million |
| Debt repayment | -128.15 Million | -37.61 Million | -150 Million | -177.47 Million | -168.04 Million | -505.8 Million |
| Dividends payments | -30.72 Million | -10.45 Million | -9.78 Million | -44.15 Million | -10.91 Million | -10.06 Million |
| Common Stock Repurchased | - | - | - | -8.36 Million | -4.18 Million | -4.18 Million |
| Common Stock Issuance | - | - | - | 3.72 Million | 3.72 Million | - |
| Other Financing Activities | -14.57 Million | 3.49 Million | -13.94 Million | 372.45 Million | 394.68 Million | 519.16 Million |
| Accounts receivables | - | -95.65 Million | - | -94.41 Million | 85.12 Million | 264.65 Million |
| Accounts payables | - | - | - | 245.2 Million | - | - |
| Inventory | - | -11.63 Million | - | -119.58 Million | -43.11 Million | 33.35 Million |
| Other working capital | - | - | - | -2.00 | - | - |
| Cash at beginning of period | 3.14 Billion | 2.84 Billion | 2.95 Billion | 2.43 Billion | 2.76 Billion | 2.53 Billion |
| Cash at end of period | 3.03 Billion | 3.17 Billion | 2.79 Billion | 3.06 Billion | 3.06 Billion | 2.67 Billion |
| Capital Expenditure | -36.15 Million | -15.9 Million | -14.74 Million | -86.53 Million | -46.19 Million | -14.8 Million |
| Effect of forex changes on cash | -262.78 Thousand | 236.57 Thousand | -165.25 Thousand | 923.88 Thousand | -1.5 Million | -306.27 Thousand |
| Net cash flow / Change in cash | -104.01 Million | 330.68 Million | -159.43 Million | 626.9 Million | 294.76 Million | 139.63 Million |
| Free Cash Flow | 68.87 Million | 328.52 Million | -285.54 Million | 863.72 Million | 97.95 Million | 259.24 Million |
UPR
GENSOL
MPSYF
5532
278280
0ZC0